Melanoma Research

Melanoma research focuses on checkpoint inhibition, adjuvant therapy strategies, resistance biology, and biomarker-driven treatment sequencing.

Our Melanoma Analysis

• July 13, 2026Nature MedicineDYP688 First-in-Human Study (NCT05415072)

  First-in-Human ADC Shows Early Activity in GNAQ/GNA11-Mutant Uveal Melanoma

  Phase 1, first-in-human dose-escalation trial of DYP688 — an antibody-drug conjugate that targets the melanocyte antigen PMEL and delivers a Gq/11 signaling inhibitor payload — in 66 patients with metastatic uveal melanoma and other GNAQ/GNA11-mutant melanomas, a population largely excluded from the only approved therapy for this disease.

• July 22, 2026Clinical Cancer ResearchMONETTE (NCT05061134)

  MONETTE Phase II Trial: Ceralasertib Combinations Fall Short in PD-(L)1-Resistant Melanoma

  Randomized (2:1), open-label, international phase II trial of ceralasertib (an oral ATR inhibitor) plus durvalumab versus ceralasertib monotherapy in 151 patients with advanced melanoma that had progressed on prior anti-PD-(L)1 therapy

• February 13, 2026Lancet OncologyKEYVIBE-010 (NCT05665595)

  KEYVIBE-010: Adding Vibostolimab to Pembrolizumab Does Not Improve Outcomes in Resected High-Risk Melanoma

  Randomised, double-blind, phase 3 study of 1,402 patients with surgically resected stage IIB–IV cutaneous melanoma across 205 global sites